经导管动脉化疗栓塞术：已有30多年的历史。
Transcatheter arterial chemoembolization: history for more than 30 years.
作者信息
Guan Yong-Song, He Qing, Wang Ming-Quan
机构信息
Department of Oncology, West China Hospital of Sichuan University, Chengdu 610041, China.
出版信息
ISRN Gastroenterol. 2012;2012:480650. doi: 10.5402/2012/480650. Epub 2012 Aug 26.
Abstract
Transcatheter arterial chemoembolization (TACE) is a minimally invasive technique to treat liver tumors, particularly hepatocellular carcinoma (HCC). TACE was used in early times to treat liver tumor patients with emergencies caused by symptomatic humoral hypercalcemia and develops gradually from the procedures of diagnostic angiography and transcatheter injection of agents and is in particular performed in the treatment of HCC. Since the beginning of this century, TACE has been used extensively in the palliative treatment of unresectable HCC. In recent years, it is indicated in selected patients with early-stage HCC. This review introduces the evolution of TACE for more than 30 years, its role in comprehensive treatment of HCC, the tendency of its refinement in future, and the combination use of TACE with other local ablative methods for the curative result of HCC.
摘要
经动脉化疗栓塞术（TACE）是一种治疗肝脏肿瘤，特别是肝细胞癌（HCC）的微创技术。TACE早期用于治疗因症状性体液高钙血症引起紧急情况的肝脏肿瘤患者，它从诊断性血管造影和经导管注射药物的操作逐渐发展而来，尤其用于HCC的治疗。自本世纪初以来，TACE已广泛应用于不可切除HCC的姑息治疗。近年来，它也适用于部分早期HCC患者。本文综述了TACE三十多年来的发展历程、其在HCC综合治疗中的作用、未来精细化的趋势，以及TACE与其他局部消融方法联合使用对HCC的治疗效果。
相似文献
1
Transcatheter arterial chemoembolization: history for more than 30 years.
ISRN Gastroenterol. 2012;2012:480650. doi: 10.5402/2012/480650. Epub 2012 Aug 26.
2
Transarterial chemoembolization for hepatocellular carcinoma: A review of techniques.
World J Hepatol. 2014 Dec 27;6(12):844-50. doi: 10.4254/wjh.v6.i12.844.
3
Sulfamethazine-based pH-sensitive hydrogels with potential application for transcatheter arterial chemoembolization therapy.
Acta Biomater. 2016 Sep 1;41:253-63. doi: 10.1016/j.actbio.2016.05.018. Epub 2016 May 13.
4
The safety and efficacy of balloon-occluded transcatheter arterial chemoembolization for hepatocellular carcinoma refractory to conventional transcatheter arterial chemoembolization.
Eur Radiol. 2020 Oct;30(10):5650-5662. doi: 10.1007/s00330-020-06911-9. Epub 2020 May 15.
5
Efficacy of combination therapy with transcatheter arterial chemoembolization and radiofrequency ablation for intermediate-stage hepatocellular carcinoma.
Scand J Gastroenterol. 2018 Dec;53(12):1575-1583. doi: 10.1080/00365521.2018.1548645. Epub 2018 Dec 21.
6
Transcatheter arterial chemoembolization vs. chemoinfusion for unresectable hepatocellular carcinoma in patients with major portal vein thrombosis.
Aliment Pharmacol Ther. 2009 Jun 15;29(12):1291-8. doi: 10.1111/j.1365-2036.2009.04016.x. Epub 2009 Apr 8.
7
Comparative study of cisplatin and epirubicin in transcatheter arterial chemoembolization for hepatocellular carcinoma.
Hepatol Res. 2011 Apr;41(4):303-9. doi: 10.1111/j.1872-034X.2010.00770.x. Epub 2011 Jan 30.
8
Comparing the long-term efficacy of standard and combined minimally invasive procedures for unresectable HCC: a mixed treatment comparison.
Oncotarget. 2017 Feb 28;8(9):15101-15113. doi: 10.18632/oncotarget.13145.
9
Reactivation of tuberculosis in hepatocellular carcinoma treated with transcatheter arterial chemoembolization: A report of 3 cases.
World J Radiol. 2012 May 28;4(5):236-40. doi: 10.4329/wjr.v4.i5.236.
10
The Degree of Lipiodol Accumulation Can Be an Indicator of Successful Treatment for Unresectable Hepatocellular Carcinoma (HCC) Patients - in the Case of Transcatheter Arterial Chemoembolization (TACE) and External Beam Radiotherapy (EBRT).
J Cancer. 2016 Jul 4;7(11):1413-20. doi: 10.7150/jca.15405. eCollection 2016.
引用本文的文献
1
Impact of microvascular invasion risk on tumor progression of hepatocellular carcinoma after conventional transarterial chemoembolization.
Oncologist. 2025 Feb 6;30(2). doi: 10.1093/oncolo/oyae286.
2
Applications of image-guided locoregional transarterial chemotherapy in patients with inoperable colorectal cancer: a review.
Front Oncol. 2024 Aug 23;14:1464242. doi: 10.3389/fonc.2024.1464242. eCollection 2024.
3
Cardio-Oncoimmunology: Cardiac Toxicity, Cardiovascular Hypersensitivity, and Kounis Syndrome.
Life (Basel). 2024 Mar 18;14(3):400. doi: 10.3390/life14030400.
4
Intratumoral and peritumoral radiomics based on contrast-enhanced MRI for preoperatively predicting treatment response of transarterial chemoembolization in hepatocellular carcinoma.
BMC Cancer. 2023 Oct 24;23(1):1026. doi: 10.1186/s12885-023-11491-0.
5
Recent Advances in Image-Guided Locoregional Therapies for Primary Liver Tumors.
Biology (Basel). 2023 Jul 13;12(7):999. doi: 10.3390/biology12070999.
6
Recent Advances in Locoregional Therapy of Hepatocellular Carcinoma.
Cancers (Basel). 2023 Jun 26;15(13):3347. doi: 10.3390/cancers15133347.
7
Review of cancer therapies for the perioperative physician.
Perioper Med (Lond). 2023 Jun 13;12(1):25. doi: 10.1186/s13741-023-00315-1.
8
MRI-based radiomics model and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.
BMC Med Imaging. 2023 May 30;23(1):67. doi: 10.1186/s12880-023-01030-5.
9
Interventional nanotheranostics in hepatocellular carcinoma.
Nanotheranostics. 2023 Jan 9;7(2):128-141. doi: 10.7150/ntno.80120. eCollection 2023.
10
Transarterial Chemoembolization and Unresectable Hepatocellular Carcinoma: A Narrative Review.
Cureus. 2022 Aug 26;14(8):e28439. doi: 10.7759/cureus.28439. eCollection 2022 Aug.
本文引用的文献
1
Transcatheter arterial chemoembolization confers survival benefit in patients with a spontaneously ruptured hepatocellular carcinoma.
Eur J Gastroenterol Hepatol. 2012 Jun;24(6):640-5. doi: 10.1097/MEG.0b013e3283524d32.
2
Effect of resection following downstaging of unresectable hepatocelluar carcinoma by transcatheter arterial chemoembolization.
Chin Med J (Engl). 2012 Jan;125(2):197-202.
3
4
Analysis of survival predictors in a prospective cohort of patients undergoing transarterial chemoembolization for hepatocellular carcinoma in a single Canadian centre.
HPB (Oxford). 2012 Mar;14(3):162-70. doi: 10.1111/j.1477-2574.2011.00420.x. Epub 2012 Jan 9.
5
An overview of evidence-based management of hepatocellular carcinoma: a meta-analysis.
J Cancer Res Ther. 2011 Oct-Dec;7(4):463-75. doi: 10.4103/0973-1482.92023.
6
Superselective transarterial chemoembolization for hepatocellular carcinoma: recent progression and perspective.
Oncology. 2011;81 Suppl 1:105-10. doi: 10.1159/000333269. Epub 2011 Dec 22.
7
Clinical trial of cisplatin-conjugated gelatin microspheres for patients with hepatocellular carcinoma.
Jpn J Radiol. 2012 Jan;30(1):62-8. doi: 10.1007/s11604-011-0010-2. Epub 2011 Dec 17.
8
Superselective transarterial chemoembolization for hepatocellular carcinoma. Validation of treatment algorithm proposed by Japanese guidelines.
J Hepatol. 2012 Apr;56(4):886-92. doi: 10.1016/j.jhep.2011.10.021. Epub 2011 Dec 13.
9
Future treatment option for hepatocellular carcinoma: a focus on brivanib.
Dig Dis. 2011;29(3):316-20. doi: 10.1159/000327568. Epub 2011 Aug 9.
10
Trans-arterial chemoembolization (TACE) in patients with unresectable Hepatocellular carcinoma: Experience from a tertiary care centre in India.
Indian J Radiol Imaging. 2011 Apr;21(2):113-20. doi: 10.4103/0971-3026.82294.
Zotero 插件